{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T05:15:29Z","timestamp":1697260529001},"reference-count":24,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,4,24]],"date-time":"2006-04-24T00:00:00Z","timestamp":1145836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2006,5]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> The aim of the study was to assess the incidence and the cumulative probability of cytolytic and cholestatic hepatotoxicity during antiretroviral treatment in a group of HIV HCV haemophiliacs. We evaluated 47 patients that received 246 courses of antiretroviral treatment [98 courses of pre\u2010highly active antiretroviral therapy (pre\u2010HAART) and 148 HAART treatments]. Liver function tests were assessed at baseline of each treatment, after 1\u2003month and at least every 4\u2003months thereafter. Cytolytic and cholestatic hepatotoxicity was recorded. Of the 246 treatments, 28 (12.45%) were followed by cytolytic hepatotoxicity and 32 (13%) by cholestatic hepatotoxicity. Cytolytic hepatotoxicity was similar in HAART (16\/148; 10.8%) and in pre\u2010HAART treatment (12\/98; 12.2%) and cholestatic hepatotoxicity was more frequent in HAART (29\/148; 19.6%) than in pre\u2010HAART treatment (3\/98; 3.1%) (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001). The actuarial probability of developing cytolytic and cholestatic hepatotoxicity at 10\u2003years of onset of antiretroviral treatments was 39% and 56%, respectively. Most enzyme elevations were asymptomatic, but in eight cases therapy was discontinued or changed and in one case a cirrhotic patient died of progressive liver failure. In HIV HCV haemophiliacs, the cumulative probability of developing hepatotoxicity during follow\u2010up is high and although in the most cases the toxicity is mild, fatal cases can occur.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2006.01211.x","type":"journal-article","created":{"date-parts":[[2006,4,24]],"date-time":"2006-04-24T10:03:32Z","timestamp":1145873012000},"page":"228-236","source":"Crossref","is-referenced-by-count":7,"title":["Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade"],"prefix":"10.1111","volume":"12","author":[{"given":"S.","family":"SAULEDA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"MARTORELL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. I.","family":"ESTEBAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"TURAL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"RUIZ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"PUIG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"ESTEBAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"GUARDIA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"VARGAS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,4,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890330307"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-112-5-379"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199912030-00002"},{"key":"e_1_2_6_5_2","first-page":"962","volume-title":"Hepatology. A Textbook of Liver Disease","author":"Bass NM","year":"1996"},{"key":"e_1_2_6_6_2","volume-title":"Table for Grading Severity of Adult Adverse Experiences","author":"AIDS Clinical Trials Group","year":"1996"},{"key":"e_1_2_6_7_2","unstructured":"ReislerR LiouS ServossJet al.Incidence of hepatotoxicity and mortality in 21 adult antiretroviral treatment trials. Program and Abstracts of the 1st IAC conference on HIV Pathogenesis and Treatment; Buenos Aires Argentina.2001. Abstract43."},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.1.74"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/341084"},{"key":"e_1_2_6_10_2","doi-asserted-by":"crossref","first-page":"A54","DOI":"10.1016\/S0016-5085(01)80265-1","article-title":"Hepatotoxicity in the US Adults Clinical Trial Group","volume":"120","author":"Servoss JC","year":"2001","journal-title":"Gastroenterology"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1310\/N4VT-3E9U-4BKN-CRPW"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.30319"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-39948"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200107060-00007"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/324629"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510230505"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05459.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200310170-00007"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200306010-00005"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200303010-00004"},{"key":"e_1_2_6_21_2","first-page":"236A","article-title":"Predictors of HAART induced hepatotoxicity in patients with HIV and Hepatitis C","volume":"36","author":"Servin L","year":"2002","journal-title":"Hepatology"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0270-9139(03)80113-1"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.19.2526"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14844-1"},{"key":"e_1_2_6_25_2","first-page":"65","article-title":"Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy","volume":"30","author":"Nu\u00f1ez M","year":"2002","journal-title":"JAIDS"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2006.01211.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2006.01211.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T17:56:22Z","timestamp":1697219782000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2006.01211.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,24]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["10.1111\/j.1365-2516.2006.01211.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2006.01211.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,24]]}}}